Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

It’s a mechanism explored some years ago when Eli Lilly was trying to develop an M1 agonist called xanomeline in Alzheimer’s, although that programme that eventually abandoned by the

Latest news

  • Teva wins FDA OK for crucial migraine drug Teva wins FDA OK for crucial migraine drug

    ahead of late-stage rivals from Eli Lilly (galcanezumab) and Alder Biopharma (eptinezumab). ... Each drug has its own set of advantages; Aimovig will be the first to market, Eli Lilly’s has significant experience in marketing drugs, and an extensive

  • New data keeps AbbVie’s star pipeline therapies on track New data keeps AbbVie’s star pipeline therapies on track

    For risankizumab, the new data could be important to help AbbVie differentiate its IL-23 inhibitor from a clutch of new biologic therapies for psoriasis from Novartis, Eli Lilly and Johnson ... Lilly reported positive phase II results with its

  • MSD wins key EU approval for Keytruda, Alimta combo MSD wins key EU approval for Keytruda, Alimta combo

    Immunotherapy blockbuster Keytruda has received another boost with the European approval of its use in combination with Lilly’s Alimta plus chemotherapy in non-small cell lung cancer (NSCLC).

  • Gilead, Galapagos JAK inhibitor clears phase II test Gilead, Galapagos JAK inhibitor clears phase II test

    Gilead, Galapagos JAK inhibitor clears phase II test. Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly. ... dugs from Pfizer and Eli Lilly – and a late-stage rival from AbbVie.

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Elunate (fruquintinib) will be sold in China by Chi-Med’s commercial partner Eli Lilly, although there’s no word yet on whether the two companies are inclined to develop the ... treated previously with intravenous VEGF drugs, such as Roche’s

More from news
Approximately 70 fully matching, plus 682 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 39 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics